AstraZeneca PLC / Pearl Therapeutics Inc.

Chronic Obstructive Pulmonary Disease (COPD)

Disease Overview

COPD is a progressive obstructive lung disease driven primarily by tobacco exposure, characterized by emphysema and chronic bronchitis with persistent airflow limitation. Severe disease produces frequent exacerbations, hospitalizations, and high mortality. Treatment relies on inhaled bronchodilators and corticosteroids, with triple-combination therapy reserved for the most severe patients.

Competitive Landscape

At the time of the June 2013 AstraZeneca-Pearl deal, the inhaled COPD market was dominated by GSK's Advair and Anoro/Breo Ellipta franchise, Boehringer Ingelheim's Spiriva (tiotropium) and Stiolto, plus Novartis/Sunovion's Seebri/Utibron. Pearl's PT003 (Bevespi Aerosphere, glycopyrrolate/formoterol LAMA/LABA) and PT010 (Breztri Aerosphere, budesonide/glycopyrrolate/formoterol triple) used proprietary co-suspension porous-particle MDI technology, differentiating from dry-powder Ellipta and soft-mist Spiriva Respimat platforms. The deal positioned AstraZeneca to launch the first FDA-approved triple-combination MDI for COPD, complementing existing Symbicort (budesonide/formoterol) and providing a same-device step-up pathway. CEO Pascal Soriot called triple combination 'the Holy Grail in respiratory medicine'; PT010 ultimately received FDA approval in 2020 as Breztri Aerosphere, becoming a key pillar of AZ's respiratory franchise alongside Fasenra (severe asthma). The acquisition has been broadly viewed as a strategic success given Breztri's blockbuster trajectory.